New drug may help liver transplant patients avoid dangerous bleeding
NCT ID NCT07600905
First seen May 24, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This study looked at whether a drug called avatrombopag can safely raise platelet levels in people who develop severe low platelets after a liver transplant. Researchers compared 67 patients who got the drug with 67 similar patients who received standard care. The drug helped platelets recover faster and reduced the need for blood transfusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTOPERATIVE COMPLICATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Avatrombopag (a pill that helps the body make more platelets)
What this could lead to
If confirmed, this could offer a new treatment option for dangerously low platelets after liver transplant, reducing bleeding risk and transfusion needs.
What could go wrong
This is a small, retrospective study, not a randomized trial. Results may not apply to all patients, and long-term safety is not fully known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.